Nasus Pharma Ltd. (NYSE: NSRX) reported positive Phase 2 results for its intranasal epinephrine powder NS002 and plans to initiate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE